Active, not recruitingPHASE1, PHASE2NCT06664502
A 2-part Study Consisting of a Multiple Ascending Dose Safety Study in Participants With Macular Edema Following Branch Retinal Vein Occlusion and a Dose-finding Safety and Preliminary Efficacy Study in Participants With Either Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Studying Central retinal vein occlusion
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- EyeBiotech Ltd.
- Intervention
- EYE201(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (27)
- Scottsdale, Arizona, Scottsdale, Arizona, United States
- Modesto, CA, Modesto, California, United States
- Mountain View, California, Mountain View, California, United States
- Sacramento, CA, Sacramento, California, United States
- Sacramento, California, Sacramento, California, United States
- Deerfield Beach, FL, Deerfield Beach, Florida, United States
- Lemont, IL, Lemont, Illinois, United States
- Hagerstown, Maryland, Hagerstown, Maryland, United States
- Madison, Mississippi, Madison, Mississippi, United States
- Bloomfield, New Jersey, Bloomfield, New Jersey, United States
- Asheville, NC, Asheville, North Carolina, United States
- Wake Forest, NC, Wake Forest, North Carolina, United States
- West Columbia, South Carolina, West Columbia, South Carolina, United States
- Germantown, Tennessee, Germantown, Tennessee, United States
- Knoxville, TN, Knoxville, Tennessee, United States
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06664502 on ClinicalTrials.govOther trials for Central retinal vein occlusion
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE4NCT07456826Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal InjectionsHarrow Inc
- ENROLLING BY INVITATIONNANCT07318428AI-Assisted Detection of Posterior Segment Diseases: DR, AMD, RVO, and GlaucomaInje University
- RECRUITINGNCT07308639DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.Bayer
- RECRUITINGPHASE2NCT07259928Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein OcclusionAnnexin Pharmaceuticals AB
- RECRUITINGEARLY PHASE1NCT04008121Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein SodiumMediBeacon
- RECRUITINGNCT07550777Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal BevacizumabAtaturk University
- RECRUITINGPHASE2NCT07205887A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVOEyeBiotech Ltd.
- RECRUITINGNANCT07002372Effect of Video Viewing on Intravitreal Injection ExperienceSecond Affiliated Hospital, School of Medicine, Zhejiang University